BIONET Therapeutics Corp.

Next-Generation, Data-Driven Exosomes from Taiwan’s Regenerative Medicine Pioneer

Since its inception in 1999, BIONET Group has spent 27 years at the forefront of regenerative and genomic medicine. It is Taiwan’s largest biotechnology conglomerate, notably becoming the first to have all three of its subsidiaries—specializing in cell therapy, genetic testing, and AI/bioinformatics—publicly listed on the stock exchange (benchmarked to the TSE Growth Market).

Proven Track Record & Global Quality Standards 
We operate Asia's largest and the world's 4th largest umbilical cord blood cell bank. Our advanced manufacturing and storage facilities hold premier international certifications, including GMP, AABB, and GTP. Our clinical legacy is backed by over 800 successful transplantations and hundreds of customized cell therapy programs.

Uncompromising Safety & Quantifiable Evidence Rooted in Regenerative Medicine
Built upon decades of stem cell research and clinical cell processing (CRDMO), BIONET’s exosomes deliver a level of quality that sets them apart from conventional cosmetic ingredients.

Utilization of Young, Highly Active USMSCs:
Sourced from umbilical cord tissue, which is significantly younger and possesses superior proliferative capacity compared to adipose or bone marrow alternatives. This biological vitality unlocks exceptional potential.

Safety: Rigorous donor screening and a GMP-compliant manufacturing process ensure a medical-grade safety profile.

Rich in miRNA with Quantifiable Efficacy: Densely packed with specific miRNAs and growth factors highly valued in aesthetic medicine and advanced skincare. With minimal batch-to-batch variation, all efficacy data is scientifically quantified and visualized.

Aesthetic & Anti-Aging Applications: Demonstrates outstanding potential in supporting skin elasticity, maintaining a healthy skin environment, and addressing advanced age-related skin concerns.

Through cutting-edge biotechnology, we are dedicated to delivering highly reliable and robust quality to medical professionals in Japan. Furthermore, at this exhibition, BIONET will be co-exhibiting with its official authorized distributor in Japan, Taiwan Gredmann Group.

【About Taiwan Gredmann Group】
・Founded in 1978; a comprehensive trading company specializing in biotechnology, semiconductors, electronics, and chemicals.
・The official authorized distributor for BIONET in Japan.

By combining the strengths of both companies, we will provide the optimal solutions for the Japanese market.